CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 déc. 2024 16h05 HE
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
12 déc. 2024 20h19 HE
|
CG Oncology Inc.
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Proposed Public Offering
11 déc. 2024 06h17 HE
|
CG Oncology Inc.
CG Oncology Announces Proposed Public Offering
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05 déc. 2024 07h00 HE
|
CG Oncology Inc.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
02 déc. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
02 déc. 2024 04h42 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
20 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
18 nov. 2024 10h20 HE
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc